Beyond the first procedure: outcomes of redo percutaneous mitral balloon valvuloplasty

European Heart Journal Supplements

16 November 2026
Organised by: Logo
ESC Journals

Abstract

AbstractBackground

Percutaneous mitral balloon valvuloplasty (PMBV) is an established treatment for severe, symptomatic rheumatic mitral stenosis, offering favorable procedural success and lower morbidity compared with surgical commissurotomy or mitral valve replacement in appropriately selected patients. However, restenosis remains an important long-term limitation, particularly among young and middle-aged patients in developing countries. Repeat or redo PMBV may provide a less invasive alternative to surgery in selected patients, although contemporary data regarding its safety, feasibility, and efficacy remain limited.

Methods

We conducted an observational study of consecutive patients undergoing redo PMBV for symptomatic recurrent rheumatic mitral stenosis following previous PMBV. Clinical characteristics, echocardiographic parameters, and hemodynamic measurements were assessed before and after the procedure. Procedural success, in-hospital outcomes, and procedure-related complications were recorded. Redo procedures were performed by experienced interventional cardiologists, with a gradual escalation of balloon size and procedural techniques tailored to valve morphology and procedural response, with the aim of achieving optimal valve opening while minimizing the risk of significant mitral regurgitation and other complications.

Results

A total of 60 patients with symptomatic rheumatic mitral restenosis underwent redo PMBV. The mean interval since the previous PMBV was 7.1 ± 5.3 years, and the mean age was 42.1 ± 11.1 years; 73.3% of patients were women and 33.3% had atrial fibrillation. Procedural success was achieved in 90% of patients. Mean mitral valve area increased significantly from 1.0.3 to 1.4 ± 0.2 cm2 (P < 0.001), while mean transmitral gradient decreased from 11.3 ± 5.4 to 6.9 ± 2.5 mmHg (P < 0.001). Severe mitral regurgitation occurred in 3.3% of patients and complete heart block in 2%. Two patients developed access-site hematomas, and one procedure was abandoned because the balloon could not be advanced across the mitral valve. No stroke, cardiac tamponade, or in-hospital mortality occurred.

Conclusions

Redo PMBV is a feasible and effective treatment option for selected patients with symptomatic rheumatic mitral restenosis after previous PMBV. When performed by experienced operators using careful stepwise balloon sizing and gradual procedural escalation according to valve morphology and hemodynamic response, repeat PMBV can achieve substantial improvements in mitral valve area and transmitral gradients with an acceptable complication profile. In appropriately selected patients, particularly those with favorable valve anatomy and in resource-limited settings, redo PMBV may provide a valuable alternative to repeat surgery